These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
368 related articles for article (PubMed ID: 35981785)
1. Protein kinase inhibitor ceritinib blocks ectonucleotidase CD39 - a promising target for cancer immunotherapy. Schäkel L; Mirza S; Winzer R; Lopez V; Idris R; Al-Hroub H; Pelletier J; Sévigny J; Tolosa E; Müller CE J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 35981785 [TBL] [Abstract][Full Text] [Related]
2. Ectonucleotidase CD73 and CD39 expression in non-small cell lung cancer relates to hypoxia and immunosuppressive pathways. Giatromanolaki A; Kouroupi M; Pouliliou S; Mitrakas A; Hasan F; Pappa A; Koukourakis MI Life Sci; 2020 Oct; 259():118389. PubMed ID: 32898522 [TBL] [Abstract][Full Text] [Related]
4. Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade. Yang R; Elsaadi S; Misund K; Abdollahi P; Vandsemb EN; Moen SH; Kusnierczyk A; Slupphaug G; Standal T; Waage A; Slørdahl TS; Rø TB; Rustad E; Sundan A; Hay C; Cooper Z; Schuller AG; Woessner R; Borodovsky A; Menu E; Børset M; Sponaas AM J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32409420 [TBL] [Abstract][Full Text] [Related]
5. Current perspectives and trends of CD39-CD73-eAdo/A2aR research in tumor microenvironment: a bibliometric analysis. Huang T; Ren X; Tang X; Wang Y; Ji R; Guo Q; Ma Q; Zheng Y; Hu Z; Zhou Y Front Immunol; 2024; 15():1427380. PubMed ID: 39188712 [TBL] [Abstract][Full Text] [Related]
6. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Friboulet L; Li N; Katayama R; Lee CC; Gainor JF; Crystal AS; Michellys PY; Awad MM; Yanagitani N; Kim S; Pferdekamper AC; Li J; Kasibhatla S; Sun F; Sun X; Hua S; McNamara P; Mahmood S; Lockerman EL; Fujita N; Nishio M; Harris JL; Shaw AT; Engelman JA Cancer Discov; 2014 Jun; 4(6):662-673. PubMed ID: 24675041 [TBL] [Abstract][Full Text] [Related]
8. Extracellular ATP inhibits IL-1-induced MMP-1 expression through the action of CD39/nucleotidase triphosphate dephosphorylase-1 on human gingival fibroblasts. Nemoto E; Gotoh K; Tsuchiya M; Sakisaka Y; Shimauchi H Int Immunopharmacol; 2013 Nov; 17(3):513-8. PubMed ID: 23941770 [TBL] [Abstract][Full Text] [Related]
9. Human follicular lymphoma CD39+-infiltrating T cells contribute to adenosine-mediated T cell hyporesponsiveness. Hilchey SP; Kobie JJ; Cochran MR; Secor-Socha S; Wang JC; Hyrien O; Burack WR; Mosmann TR; Quataert SA; Bernstein SH J Immunol; 2009 Nov; 183(10):6157-66. PubMed ID: 19864600 [TBL] [Abstract][Full Text] [Related]
10. High-Throughput Screening Assays for Cancer Immunotherapy Targets: Ectonucleotidases CD39 and CD73. Kumar M; Lowery R; Kumar V SLAS Discov; 2020 Mar; 25(3):320-326. PubMed ID: 31868071 [TBL] [Abstract][Full Text] [Related]
11. Targeting adenosine and regulatory T cells in cancer immunotherapy. Churov A; Zhulai G Hum Immunol; 2021 Apr; 82(4):270-278. PubMed ID: 33610376 [TBL] [Abstract][Full Text] [Related]
12. Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity. Kashyap AS; Thelemann T; Klar R; Kallert SM; Festag J; Buchi M; Hinterwimmer L; Schell M; Michel S; Jaschinski F; Zippelius A J Immunother Cancer; 2019 Mar; 7(1):67. PubMed ID: 30871609 [TBL] [Abstract][Full Text] [Related]
13. CD39 - A bright target for cancer immunotherapy. Guo S; Han F; Zhu W Biomed Pharmacother; 2022 Jul; 151():113066. PubMed ID: 35550530 [TBL] [Abstract][Full Text] [Related]
14. Adenosine and the adenosine A2A receptor agonist, CGS21680, upregulate CD39 and CD73 expression through E2F-1 and CREB in regulatory T cells isolated from septic mice. Bao R; Shui X; Hou J; Li J; Deng X; Zhu X; Yang T Int J Mol Med; 2016 Sep; 38(3):969-75. PubMed ID: 27430240 [TBL] [Abstract][Full Text] [Related]
15. Vascular CD39/ENTPD1 directly promotes tumor cell growth by scavenging extracellular adenosine triphosphate. Feng L; Sun X; Csizmadia E; Han L; Bian S; Murakami T; Wang X; Robson SC; Wu Y Neoplasia; 2011 Mar; 13(3):206-16. PubMed ID: 21390184 [TBL] [Abstract][Full Text] [Related]
16. Sulfated Polysaccharides from Macroalgae Are Potent Dual Inhibitors of Human ATP-Hydrolyzing Ectonucleotidases NPP1 and CD39. Lopez V; Schäkel L; Schuh HJM; Schmidt MS; Mirza S; Renn C; Pelletier J; Lee SY; Sévigny J; Alban S; Bendas G; Müller CE Mar Drugs; 2021 Jan; 19(2):. PubMed ID: 33499103 [TBL] [Abstract][Full Text] [Related]
17. CD73 and CD39 ectonucleotidases in T cell differentiation: Beyond immunosuppression. Bono MR; Fernández D; Flores-Santibáñez F; Rosemblatt M; Sauma D FEBS Lett; 2015 Nov; 589(22):3454-60. PubMed ID: 26226423 [TBL] [Abstract][Full Text] [Related]
18. Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer. Croegaert K; Kolesar JM Am J Health Syst Pharm; 2015 Sep; 72(17):1456-62. PubMed ID: 26294238 [TBL] [Abstract][Full Text] [Related]
19. ZYY-B-2, a novel ALK inhibitor, overcomes resistance to ceritinib by inhibiting P-gp function and induces apoptosis through mitochondrial pathway in ceritinib-resistant H2228 cells. Gao Y; Liu T; Liu J; Yang Y; Sun K; Li Z; Zhai X; Zuo D Chem Biol Interact; 2023 Jul; 379():110516. PubMed ID: 37116853 [TBL] [Abstract][Full Text] [Related]
20. The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models. Zhang S; Anjum R; Squillace R; Nadworny S; Zhou T; Keats J; Ning Y; Wardwell SD; Miller D; Song Y; Eichinger L; Moran L; Huang WS; Liu S; Zou D; Wang Y; Mohemmad Q; Jang HG; Ye E; Narasimhan N; Wang F; Miret J; Zhu X; Clackson T; Dalgarno D; Shakespeare WC; Rivera VM Clin Cancer Res; 2016 Nov; 22(22):5527-5538. PubMed ID: 27780853 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]